Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.

This study found that intralesional Diprospan injections and high-dose intravenous methylprednisolone may be effective for treating longstanding multifocal alopecia areata, with variable hair regrowth observed among patients.

In this case report, high-dose intravenous methylprednisone followed by oral prednisolone improved painful muscle cramps in a young man unresponsive to other treatments, suggesting an autoimmune mechanism may be involved.

In this case study, intravenous cyclophosphamide pulse therapy effectively improved symptoms of steroid-resistant lupus cystitis and peritonitis, allowing for a reduction in steroid dosage.

This study found that monthly high-dose steroid pulse therapy for approximately six months was effective and well-tolerated in Taiwanese patients with severe multifocal alopecia areata.

High-dose corticosteroids can significantly regrow hair in severe alopecia areata.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This study observed that while dexamethasone-cyclophosphamide pulse therapy is relatively free from hypertension and diabetes compared to conventional steroids in pemphigus patients, it frequently causes generalized weakness and flushing.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This article discusses the roles of pediatrics and dermatology departments at Yale University School of Medicine, but reports no specific clinical results.

In this case study, a 36-year-old female with severe lupus enteritis and intestinal pseudo-obstruction showed significant clinical improvement after treatment with intravenous methylprednisolone, hydroxychloroquine, and cyclophosphamide, highlighting the complexities and challenges in diagnosing and managing atypical lupus manifestations.

This case report describes improvement in amenorrhea, alopecia, and muscle spasms in a 13-year-old girl with Satoyoshi syndrome following treatment with daily tacrolimus and alternate-day oral prednisolone.

This study found that Filipino patients with lupus typically develop myocarditis early and respond well to early immunosuppressive therapy.

This study reports that Rituximab may be a safe and effective treatment for refractory juvenile systemic lupus erythematosus complicated by macrophage activation syndrome, allowing for successful steroid tapering.

This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.

This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.

Use the least toxic, most specific treatments for skin diseases, considering side effects and individual patient needs.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This review discusses the potential role of systemic corticosteroids in the treatment of progressive vitiligo, but reports no new clinical results and suggests further research is needed.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This case report describes the first observed association between alopecia areata and Kawasaki disease in a 10-year-old boy, suggesting a possible link that merits further investigation.